
    
      Double-blind, placebo controlled, parallel-design. 48 cognitively-intact subjects, and 24
      subjects with early cognitive decline (CDR 0.5) will be randomly assigned to treatment with
      gemfibrozil (600 mg orally twice a day) or placebo for 52 weeks. Safety assessments will
      include routine assessment of adverse events, safety labs, and brain magnetic resonance
      imaging.
    
  